Trial Outcomes & Findings for Apremilast in the Treatment of Uveitis (NCT NCT00889421)

Results Overview

Recruitment status

TERMINATED

Study phase

PHASE1/PHASE2

Target enrollment

3 participants

Primary outcome timeframe

6 months

Results posted on

2014-07-08

Participant Flow

Participant milestones

Participant milestones
Measure	Treatment Patient receiving apremilast.
Overall Study STARTED	3
Overall Study COMPLETED	0
Overall Study NOT COMPLETED	3

Reasons for withdrawal

Reasons for withdrawal
Measure	Treatment Patient receiving apremilast.
Overall Study Lack of Efficacy	3

Baseline Characteristics

Apremilast in the Treatment of Uveitis

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Treatment n=3 Participants Patient receiving apremilast.
Age, Categorical <=18 years	0 Participants n=5 Participants
Age, Categorical Between 18 and 65 years	3 Participants n=5 Participants
Age, Categorical >=65 years	0 Participants n=5 Participants
Sex: Female, Male Female	2 Participants n=5 Participants
Sex: Female, Male Male	1 Participants n=5 Participants
Region of Enrollment United States	3 participants n=5 Participants

PRIMARY outcome

Timeframe: 6 months

Outcome measures

Outcome data not reported

PRIMARY outcome

Timeframe: 6 months

Outcome measures

Outcome data not reported

PRIMARY outcome

Timeframe: 6 months

Outcome measures

Outcome data not reported

PRIMARY outcome

Timeframe: 6 months

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: 7 months

Outcome measures

Outcome data not reported

Adverse Events

Treatment

Serious events: 0 serious events

Other events: 1 other events

Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Other adverse events
Measure	Treatment n=3 participants at risk Patient receiving apremilast.
Gastrointestinal disorders nausea	33.3% 1/3 • Number of events 1

Additional Information

Dr. Eric Suhler

Oregon Health & Science University

Phone: 503-494-5023

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee
Publication restrictions are in place